Patient Group Pushes FDA For LASIK Ban
A group of patient advocates including one former US FDA official met with agency staff on Sept. 13 to raise awareness about adverse events tied to LASIK surgery. The group said the vision-correcting procedure is too risky to be offered as elective surgery.
You may also be interested in...
The agency posted questionnaires that it says can be used to help eye-care professionals assess patients before and after LASIK surgery and can be used by device manufacturers to support product submissions.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.